Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (9556)	11/23/2003 10:39:44 PM
From: tuck	Read Replies (2) \| Respond to of 52153

Fred, The partners walked away because it was highly probable that the unexpected incidence (however small: <0.5%) of allergic reactions would delay launch, and narrow the label and market. For PRCS, the smaller market was big enough to be worth its while. Abarelix otherwise does have a favorable side effect profile: less testosterone surge and hot flashes, and achieves medical castration faster. So even if it confers no survival benefit, it's an easier drug for patients to deal with as long as they aren't prone to those allergic reactions. I believe the new trial involved screening out such people. I think a couple of other biofreaks may still follow PRCS; perhaps they can correct any error in detail here, as I'm going from memory. Stefaan, now back from vacation, has it in his stock picking portfolio. In any case, the label is going to be fairly important. Cheers, Tuck